Hims & Hers (HIMS) Stock Rockets 39% on Novo Nordisk (NVO) Obesity Drug Partnership Deal

Key Takeaways

Table of Contents

A partnership between Novo Nordisk and Hims & Hers to distribute weight loss medications together could be revealed as early as Monday
After-hours trading saw Hims shares skyrocket 39% on the partnership news
The agreement resolves ongoing litigation, including a patent lawsuit Novo filed against Hims in recent weeks
Novo had previously ended an initial partnership with Hims due to concerns about promotional strategies and compounded medication distribution
Federal regulators had warned Hims about potential enforcement regarding its $49 compounded semaglutide alternative

A significant partnership between Novo Nordisk and Hims & Hers will bring obesity medications to the telehealth company’s platform, putting an end to a contentious legal battle that had intensified into patent litigation mere weeks earlier.

JUST IN:
Novo Nordisk $NVO plans to sell its weight-loss drugs on Hims & Hers Health's $HIMS platform – Bloomberg pic.twitter.com/iVCqiusEyY
— Evan (@StockMKTNewz) March 7, 2026

The arrangement was initially disclosed by Bloomberg News on Friday, according to sources with knowledge of the situation. The news sent Hims shares soaring 39% during after-hours trading.

Novo Nordisk A/S, NVO

Both organizations are anticipated to publicly reveal the partnership by Monday at the earliest. Details regarding the financial structure of the deal remain undisclosed.

A Dramatic Reversal in Relations

The shift in dynamics is remarkable. Only weeks ago, Novo initiated patent infringement litigation against Hims following the telehealth firm’s introduction—and subsequent withdrawal—of a $49 compounded alternative to Novo’s weight loss medication.

Federal health regulators had additionally issued warnings about potential enforcement actions against Hims related to its distribution of compounded semaglutide, the primary component in Wegovy and Ozempic.

These regulatory challenges, coupled with Novo’s legal action, created significant complications for Hims leading up to this announcement.

This marks the second attempt at cooperation between these companies. Novo terminated an earlier partnership with Hims during the previous year, expressing dissatisfaction with Hims’ promotional approaches and its ongoing distribution of generic Wegovy alternatives.

The current arrangement signals a renewed effort at working together, presumably under mutually acceptable conditions.

Strategic Implications for Both Organizations

For Novo, this collaboration provides an additional avenue for distributing its branded obesity medications amid intensifying competition within the weight loss pharmaceutical sector.

According to a Novo representative, the organization “is always in conversation with companies that can help improve patient access to FDA-approved medicines.” The company has offered limited additional public commentary.

Hims has not provided a response to inquiries regarding the partnership.

For Hims, this agreement marks a strategic shift. The company had been emphasizing compounded semaglutide as an affordable substitute for Novo’s medications.

This approach encountered obstacles when federal regulators determined that semaglutide was no longer experiencing supply shortages earlier this year, essentially removing the legal justification for compounding pharmacies to continue manufacturing it.

Current Market Position

Hims shares climbed 39% during Friday’s after-hours session. Throughout standard trading hours, both NVO and HIMS closed lower—NVO declining 1.25% while HIMS dropped 0.88%.

The official partnership announcement is anticipated no later than Monday, March 9.